Johnson & Johnson Commits Additional $2 Billion to U.S. Manufacturing Amid Pharma 'Onshoring' Wave

Another MNC demonstrates its "financial prowess" in the United States.

On August 21, 2025, Johnson & Johnson once again announced its significant investment commitment in the United States: over the next decade.Invest $2 Billion in FUJIFILM's New Biopharmaceutical Production Base in Holly Springs, North Carolina, to build a dedicated production facility exceeding 160,000 square feet. This investment will not only further expand Johnson & Johnson's advanced drug manufacturing capabilities in the United States but also bring approximately 120 new job opportunities to North Carolina.

The strategic layout in Hollisprings was announced by Johnson & Johnson on March 21 this year.A Grand Plan to Invest Over $55 Billion in the U.S. in the Next Four YearsAn important component. This investment increased by 25% compared to the previous four years.

Johnson & Johnson Chairman and CEO Joaquin Duato emphasized that Johnson & Johnson has more production facilities in the United States than in any other country, and through the recently signed "One Big Beautiful Bill Act," the company will continue to expand its investment in the U.S., leading the next era of healthcare innovation.

01

Under the "Tariff Stick," MNCs Increase Investment in the U.S.

Johnson & Johnson's major investment in the United States is not an isolated case. From Eli Lilly to Novartis, from Merck to Gilead,A political storm-driven“Reshoring of Manufacturing”Sweeping Across America. And at the center of the storm is that man — Donald Trump.

Since the beginning of this year, Trump has repeatedly hinted at imposing tariffs on imported drugs and launched a Section 232 investigation on pharmaceuticals in April. Under the continuous threat of "tariff sticks," multinational corporations (MNCs) have been increasing their investments within the United States to avoid potential tariff risks, planning to construct or expand production facilities.

According to incomplete statistics from PharmaTimes, as of now, the total amount of public investments by multinational pharmaceutical companies in the U.S. for 2025 has exceeded 350 billion US dollars. Among themJohnson & Johnson, Roche, and AstraZeneca have the largest investment in the U.S., all exceeding500Billion US dollars, ranking among the top.

02

"Price Hikes for Equality, American Style"

Under Trump's erratic policy style, MNCs face increased uncertainty in their drug pricing and strategic planning.

In the early hours of August 1, 2025, Trump once again unleashed a "Twitter storm" on his social platform Truth Social, furiously posting 17 tweets in just six minutes. The content consisted of open letters addressed to 17 multinational pharmaceutical companies, demanding that these leading pharmaceutical firms implement the "Most Favored Nation" policy within 60 days.Attempt to reduce the reimbursement prices of some Medicare drugs by comparing them with those in other countries.This may indirectly push global drug prices to align with those in the U.S., arguably a form of "price hike equality with American characteristics."

Lilly responded quickly, issuing a statement on August 14th stating: they are in consultations with some national governments, and the relevant price adjustments will be completed before September 1st, while ensuring that patient access to medications will not be affected. Among these, the agreement reached with the UK government has drawn particular attention: within the UK region,The highest dose ofMounjaro(The price of Tirzepatide for glycemic control) will start from122Pound rises to330Pound sterling, with an increase of up to170%; The price increase for low-dose products ranged between 45% and 138%. Eli Lilly explained to the Financial Times that this price adjustment aims to "address pricing disparities compared to other developed countries, including European nations."

The impact on the UK pharmaceuticals market does not stop there. AstraZeneca, a UK-based company that received an additional $50 billion in US investment, stated: Due to dissatisfaction with the increasingly severe business and investment environment in the UK, AstraZeneca...Cancellation of Investment in Vaccine Production Plant in Northern England4.5Billion-pound Plan. Moreover, AstraZeneca CEO Pascal Soriot revealed through multiple overseas media outlets such as The Times and Bloomberg,The company is considering delisting from the London Stock Exchange and moving to the U.S. for listing., in seeking a more stable and incentive-driven capital market environment.

Conclusion

Trump's wielding of the "tariff club" is reshaping the underlying logic of the global pharmaceutical industry:Innovation no longer belongs only to laboratories; it also emerges from the meeting rooms of policy negotiations.Corporate strategic decisions are no longer driven solely by science and the market, but are also influenced by a president's social dynamics.

This "Reshoring of Manufacturing" seems bustling on the surface but is, in fact, fraught with underlying tensions. In the short term, companies are using their "cash power" to secure policy safety; in the long run, however, it faces the risks of a forced reconstruction of the global supply chain and the collapse and rebuilding of the drug pricing system. As "America First" evolves into "Global Price Hikes for Equity," the ones footing the bill may not only be the healthcare insurance systems but also the cornerstone of global patients' trust in the pharmaceutical industry. Whether this "Great Pharmaceutical Migration" ignited by politics will drive innovation or exacerbate divisions, only time will tell. PharmaTimes will continue to monitor the situation.

References:

1.https://www.biospace.com/business/j-j-adds-2b-to-us-manufacturing-commitment-amid-trumps-protracted-tariff-threats

2. (WeChat Official Account: PharmTimes)

3. (WeChat Official Account: PharmTimes)

4.MNC "Rush to Capture" Intensifies! Gilead, Takeda Pave the Way with Billions, Over 10 Giants Enter the Fray... (WeChat Official Account: Yidu Pharma)

5. Lilly, Johnson & Johnson and More Than a Dozen Other Pharma Giants Announce Factory Construction in the U.S., with a Total Investment Exceeding 2 Trillion Yuan! Enough to Build 640 Bird's Nest Stadiums (WeChat Official Account: Dingxiangyuan Insight Database)

6. Other Public Information

Join the reader communication group:

Business Cooperation:Xiaoyu Yang 15210041717